A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
02/09/2021
Autori: Lori J. Goldstein, Mauro Mansutti, Christelle Levy, Jenny C. Chang, Stephanie Henry, Isaura Fernandez-Perez, Jana Prausov�, Elzbieta Staroslawska, Giuseppe Viale, Beth Butler, Susan McCanna, Pier Adelchi Ruffini, Max S. Wicha & Anne F. Schott for the fRida Trial Investigators
Pubblicato in:
Breast Cancer Research and Treatment